renal cell carcinoma Archives -

BMS gets an important win for Opdivo combination in kidney cancer

https://pharmaphorum.com/news/bms-gets-an-important-win-for-opdivo-combination-in-kidney-cancer/

BMS builds case for long-term use of Opdivo in kidney cancer

https://pharmaphorum.com/news/bms-builds-case-for-long-term-use-of-opdivo-in-kidney-cancer/

NICE rejects MSD/Pfizer’s combination in untreated kidney cancer

https://pharmaphorum.com/news/nice-rejects-msd-pfizers-combination-in-untreated-kidney-cancer/

Immunicum shares fall despite “fantastic” kidney cancer data

https://pharmaphorum.com/news/immunicum-shares-fall-despite-fantastic-kidney-cancer-data/

Merck and Pfizer’s Bavencio approved for renal cell carcinoma

https://pharmaphorum.com/news/merck-and-pfizers-bavencio-approved-for-renal-cell-carcinoma/

Keytruda combo set to become “standard of care” in kidney cancer

https://pharmaphorum.com/news/keytruda-combo-set-to-become-standard-of-care-kidney-cancer/

Clinigen buys remaining rights to Novartis cancer drug

https://pharmaphorum.com/news/clinigen-buys-remaining-rights-to-novartis-cancer-drug/

EU approves Ipsen’s Cabometyx in first line kidney cancer

https://pharmaphorum.com/news/eu-approves-ipsens-cabometyx-in-first-line-kidney-cancer/

Roche’s Tecentriq + Avastin racks up another combination success

https://pharmaphorum.com/news/tecentriq-avastin-combination-success/

Search